دورية أكاديمية
أعرض في EDS

Umbilical cord blood CD34 + progenitor-derived NK cells efficiently kill ovarian cancer spheroids and intraperitoneal tumors in NOD/SCID/IL2Rg null mice.

التفاصيل البيبلوغرافية
العنوان: Umbilical cord blood CD34 + progenitor-derived NK cells efficiently kill ovarian cancer spheroids and intraperitoneal tumors in NOD/SCID/IL2Rg null mice.
المؤلفون: Hoogstad-van Evert JS; Department of Laboratory Medicine, Laboratory of Hematology, Radboud University Medical Center, Nijmegen, the Netherlands.; Department of Obstetrics and Gynecology, Radboud University Medical Center, Nijmegen, the Netherlands., Cany J; Department of Laboratory Medicine, Laboratory of Hematology, Radboud University Medical Center, Nijmegen, the Netherlands., van den Brand D; Department of Biochemistry, Radboud University Medical Center, Nijmegen, the Netherlands., Oudenampsen M; Department of Laboratory Medicine, Laboratory of Hematology, Radboud University Medical Center, Nijmegen, the Netherlands., Brock R; Department of Biochemistry, Radboud University Medical Center, Nijmegen, the Netherlands., Torensma R; Department of Tumor Immunology, Radboud University Medical Center, Nijmegen, the Netherlands., Bekkers RL; Department of Obstetrics and Gynecology, Radboud University Medical Center, Nijmegen, the Netherlands., Jansen JH; Department of Laboratory Medicine, Laboratory of Hematology, Radboud University Medical Center, Nijmegen, the Netherlands., Massuger LF; Department of Obstetrics and Gynecology, Radboud University Medical Center, Nijmegen, the Netherlands., Dolstra H; Department of Laboratory Medicine, Laboratory of Hematology, Radboud University Medical Center, Nijmegen, the Netherlands.
المصدر: Oncoimmunology [Oncoimmunology] 2017 May 11; Vol. 6 (8), pp. e1320630. Date of Electronic Publication: 2017 May 11 (Print Publication: 2017).
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101570526 Publication Model: eCollection Cited Medium: Print ISSN: 2162-4011 (Print) Linking ISSN: 21624011 NLM ISO Abbreviation: Oncoimmunology Subsets: PubMed not MEDLINE
أسماء مطبوعة: Publication: 2015- : Philadelphia, PA : Taylor & Francis
Original Publication: Austin, TX : Landes Bioscience
مستخلص: Adoptive transfer of allogeneic natural killer (NK) cells is an attractive therapy approach against ovarian carcinoma. Here, we evaluated the potency of highly active NK cells derived from human CD34+ haematopoietic stem and progenitor cells (HSPC) to infiltrate and mediate killing of human ovarian cancer spheroids using an in vivo -like model system and mouse xenograft model. These CD56+Perforin+ HSPC-NK cells were generated under stroma-free conditions in the presence of StemRegenin-1, IL-15, and IL-12, and exerted efficient cytolytic activity and IFNγ production toward ovarian cancer monolayer cultures. Live-imaging confocal microscopy demonstrated that these HSPC-NK cells actively migrate, infiltrate, and mediate tumor cell killing in a three-dimensional multicellular ovarian cancer spheroid. Infiltration of up to 30% of total HSPC-NK cells within 8 h resulted in robust tumor spheroid destruction. Furthermore, intraperitoneal HSPC-NK cell infusions in NOD/SCID-IL2Rγ null (NSG) mice bearing ovarian carcinoma significantly reduced tumor progression. These findings demonstrate that highly functional HSPC-NK cells efficiently destruct ovarian carcinoma spheroids in vitro and kill intraperitoneal ovarian tumors in vivo , providing great promise for effective immunotherapy through intraperitoneal HSPC-NK cell adoptive transfer in ovarian carcinoma patients.
References: Stem Cells Dev. 2015 Dec 15;24(24):2886-98. (PMID: 26414401)
Proc Natl Acad Sci U S A. 2013 Apr 16;110(16):6488-93. (PMID: 23576740)
Cancer J. 2015 Nov-Dec;21(6):486-91. (PMID: 26588681)
Cancer Immunol Immunother. 2017 Jan;66(1):129-140. (PMID: 27858101)
PLoS One. 2011;6(6):e20740. (PMID: 21698239)
Front Immunol. 2014 Apr 17;5:176. (PMID: 24860566)
Biochem Biophys Res Commun. 2012 Oct 19;427(2):373-8. (PMID: 22995296)
Blood. 2014 Jun 19;123(25):3855-63. (PMID: 24719405)
Scand J Immunol. 2011 Sep;74(3):244-52. (PMID: 21595734)
Immunity. 2010 Oct 29;33(4):632-44. (PMID: 20951068)
Clin Cancer Res. 2016 Feb 1;22(3):596-608. (PMID: 26423796)
Clin Cancer Res. 2005 Jan 1;11(1):67-72. (PMID: 15671529)
PLoS One. 2010 Feb 15;5(2):e9221. (PMID: 20169160)
Immunotherapy. 2011 Dec;3(12):1445-59. (PMID: 22091681)
BMC Cancer. 2015 May 03;15:351. (PMID: 25933805)
Cytotherapy. 2011 Jan;13(1):98-107. (PMID: 20849361)
J Immunol. 2015 Oct 15;195(8):4010-9. (PMID: 26363055)
PLoS One. 2007 Mar 28;2(3):e326. (PMID: 17389917)
Front Immunol. 2015 Nov 02;6:543. (PMID: 26579120)
Cancer Res. 2006 Jun 15;66(12):6387-94. (PMID: 16778217)
J Immunol. 2011 Feb 1;186(3):1538-45. (PMID: 21191066)
Proc Natl Acad Sci U S A. 2011 Jun 28;108(26):10656-61. (PMID: 21670276)
Blood. 2005 Apr 15;105(8):3051-7. (PMID: 15632206)
PLoS One. 2013 Jun 05;8(6):e64384. (PMID: 23755121)
Front Biosci (Landmark Ed). 2017 Jan 1;22:370-384. (PMID: 27814619)
Cytotherapy. 2013 Oct;15(10):1297-306. (PMID: 23993303)
J Transl Med. 2006 Nov 14;4:49. (PMID: 17105663)
Nat Methods. 2012 Jun 28;9(7):676-82. (PMID: 22743772)
J Cancer. 2013;4(1):12-24. (PMID: 23386901)
CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29. (PMID: 25559415)
BMC Med. 2016 Oct 21;14 (1):163. (PMID: 27769244)
Cell Transplant. 2011;20(11-12):1731-46. (PMID: 21669033)
Oncotarget. 2016 Feb 9;7(6):7318-28. (PMID: 26802025)
Stem Cells Dev. 2004 Jun;13(3):307-14. (PMID: 15186726)
Oncoimmunology. 2015 Apr 1;4(7):e1017701. (PMID: 26140247)
Nat Protoc. 2009;4(3):309-24. (PMID: 19214182)
Stem Cells. 2016 Jan;34(1):93-101. (PMID: 26503833)
Front Immunol. 2015 Apr 28;6:195. (PMID: 25972867)
Sci China Life Sci. 2015 Dec;58(12):1288-98. (PMID: 26588911)
Hum Pathol. 1994 Mar;25(3):263-70. (PMID: 7512074)
فهرسة مساهمة: Keywords: Adoptive immunotherapy; NK cells; mouse ovarian cancer xenograft; ovarian cancer; tumor spheroid infiltration
تواريخ الأحداث: Date Created: 20170919 Latest Revision: 20210112
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC5593716
DOI: 10.1080/2162402X.2017.1320630
PMID: 28919991
قاعدة البيانات: MEDLINE
الوصف
تدمد:2162-4011
DOI:10.1080/2162402X.2017.1320630